Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Ital ...

Financially, Creative Medical has limited cash reserves, high cash burn, and will likely need dilutive financing. Click here ...

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...

Century Therapeutics (NASDAQ: IPSC) is a clinical-stage biotechnology company leveraging its expertise in cellular reprogramming, genetic engineering, and manufacturing to develop cell therapies ...

Aspen Neuroscience has released 6-month data from the first three patients dosed in the ASPIRO Phase 1/2a trial of ANPD001, an investigational autologous dopaminergic neuronal precursor cell (DANPC) ...

Are we close to generating a bioengineered human heart? Camila Hochman-Mendez weighs in on recent advances and remaining ...

Side-by-side modeling of iPSC-derived neurons (iPSCsNs ... Activated T cells undergo metabolic reprogramming to optimize effector functions, but the underlying mechanisms remain elusive.

However, even though already 20 years have passed since their discovery, the production of iPSC-based therapies is still associated with a number of hurdles due to low reprogramming efficiency, the ...

Its core technologies include cell reprogramming technology, stem cell culture based on microcarrier technology, and the establishment and management of induced pluripotent stem cells (iPSC ...

Creative Biolabs' new service portfolio encompasses the full iPSC workflow, offering end-to-end assistance from reprogramming to early stages to downstream differentiation. "We understand the ...